18831744

Source:http://linkedlifedata.com/resource/pubmed/id/18831744

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0034380, umls-concept:C0034656, umls-concept:C0041703, umls-concept:C0205081, umls-concept:C0205082, umls-concept:C0282461, umls-concept:C0332161, umls-concept:C0406317, umls-concept:C0683971, umls-concept:C1122087, umls-concept:C1274040, umls-concept:C1707455, umls-concept:C2587213
pubmed:dateCreated	2008-11-6
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00237887
pubmed:abstractText	To evaluate the impact of adalimumab on health-related quality of life (HRQOL) for patients with moderate to severe plaque psoriasis.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-10459113, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-10906652, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-11255325, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-11501512, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-11703288, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-11763202, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-12271293, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-12553852, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-12752139, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-12771471, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-14627786, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-14676082, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-14679270, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-15083779, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-15892420, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-16307657, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-16484818, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-16704649, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-17010738, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-17365264, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-17936411, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-18047521, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-18058494, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-18177782, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-9505733, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-9544596, http://linkedlifedata.com/resource/pubmed/commentcorrection/18831744-9859917
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101153626
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha, http://linkedlifedata.com/resource/pubmed/chemical/adalimumab
pubmed:status	MEDLINE
pubmed:issn	1477-7525
pubmed:author	pubmed-author:FeldmanStevenS, pubmed-author:HarnamNeeshaN, pubmed-author:KimelMiriamM, pubmed-author:MenterAlanA, pubmed-author:RevickiDennis ADA, pubmed-author:WillianMary KMK
pubmed:issnType	Electronic
pubmed:volume	6
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	75
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:18831744-Adult, pubmed-meshheading:18831744-Age Factors, pubmed-meshheading:18831744-Anti-Inflammatory Agents, pubmed-meshheading:18831744-Antibodies, Monoclonal, pubmed-meshheading:18831744-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18831744-Antirheumatic Agents, pubmed-meshheading:18831744-Female, pubmed-meshheading:18831744-Humans, pubmed-meshheading:18831744-Injections, Subcutaneous, pubmed-meshheading:18831744-Male, pubmed-meshheading:18831744-Middle Aged, pubmed-meshheading:18831744-Psoriasis, pubmed-meshheading:18831744-Psychometrics, pubmed-meshheading:18831744-Quality of Life, pubmed-meshheading:18831744-Sex Factors, pubmed-meshheading:18831744-Sickness Impact Profile, pubmed-meshheading:18831744-Skin, pubmed-meshheading:18831744-Treatment Outcome, pubmed-meshheading:18831744-Tumor Necrosis Factor-alpha, pubmed-meshheading:18831744-United States, pubmed-meshheading:18831744-Young Adult
pubmed:year	2008
pubmed:articleTitle	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
pubmed:affiliation	Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland, USA. dennis.revicki@unitedbiosource.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III